Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo
- PMID: 24618544
- PMCID: PMC4070794
- DOI: 10.1086/674327
Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo
Abstract
Abstract The purpose of this study was to investigate whether acute intravenous administration of the phosphodiesterase type 5 (PDE-5) inhibitor sildenafil in a single clinically relevant dose improves the in vivo function of the hypertrophic and failing right ventricle (RV). Wistar rats ([Formula: see text]) were subjected to pulmonary trunk banding (PTB) causing RV hypertrophy and failure. Four weeks after surgery, they were randomized to receive an intravenous bolus dose of sildenafil (1 mg/kg; [Formula: see text]), vehicle ([Formula: see text]), or dobutamine (10 μg/kg; [Formula: see text]). Invasive RV pressures were recorded continuously, and transthoracic echocardiography was performed 1, 5, 15, 25, 35, 50, 70, and 90 minutes after injecting the bolus. Cardiac function was compared to baseline measurements to evaluate the in vivo effects of each specific treatment. The PTB procedure caused significant hypertrophy, cardiac fibrosis, and reduction in RV function evaluated by echocardiography (TAPSE) and invasive pressure measurements. Sildenafil did not improve the function of the hypertrophic failing right heart in vivo, measured by TAPSE, RV systolic pressure (RVsP), and dp/dtmax. Dobutamine improved RV function 1 minute after injection measured by TAPSE ([Formula: see text] vs. [Formula: see text] cm; [Formula: see text]), RVsP ([Formula: see text] vs. [Formula: see text] mmHg; [Formula: see text]), and dp/dtmax ([Formula: see text] vs. [Formula: see text] mmHg/s; [Formula: see text]). Acute administration of the PDE-5 inhibitor sildenafil in a single clinically relevant dose did not modulate the in vivo function of the hypertrophic failing right heart of the rat measured by echocardiography and invasive hemodynamics. In the same model, dobutamine acutely improved RV function.
Figures
; three asterisks,
. Numbers plotted in the columns denote the number of animals used for analysis. RVW/LV+SW, right ventricle/left ventricle plus septum weight; TAPSE, tricuspid annular plane systolic excursion measured by transthoracic echocardiography; RVsP, right ventricular systolic pressure; dp/dtmax, maximum pressure development over time. PTB, pulmonary trunk banding; veh, vehicle; sil, sildenafil; dob, dobutamine.
. Numbers plotted in the column denote the number of animals used for analysis. RVsP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion measured by transthoracic echocardiography; dp/dtmax, maximum pressure development over time; PTB, pulmonary trunk banding; ns, not significant.
; three asterisks,
compared to baseline measurement. TAPSE, tricuspid annular plane systolic excursion measured by transthoracic echocardiography; RVsP, right ventricular systolic pressure; RVPP, right ventricular pulse pressure product; dp/dtmax, maximum pressure development over time; dp/dtmin, minimum pressure development over time.
; two asterisks,
; three asterisks,
compared to baseline measurement. TAPSE, tricuspid annular plane systolic excursion measured by transthoracic echocardiography; RVsP, right ventricular systolic pressure; RVPP, right ventricular pulse pressure product; dp/dtmax, maximum pressure development over time; dp/dtmin, minimum pressure development over time.
compared to baseline measurement. TAPSE, tricuspid annular plane systolic excursion measured by transthoracic echocardiography; RVsP, right ventricular systolic pressure; RVPP, right ventricular pulse pressure product; dp/dtmax, maximum pressure development over time; dp/dtmin, minimum pressure development over time.
; two asterisks,
compared to baseline measurement. TAPSE, tricuspid annular plane systolic excursion measured by transthoracic echocardiography; RVsP, right ventricular systolic pressure; RVPP, right ventricular pulse pressure product; dp/dtmax, maximum pressure development over time; dp/dtmin, minimum pressure development over time.References
-
- Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11(2):214–222. - PubMed
-
- Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 2008;10(12):1158–1165. - PubMed
-
- Schäfer S, Ellinghaus P, Janssen W, et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 2009;82(1):30–39. - PubMed
-
- Borgdorff MAJ, Bartelds B, Dickinson MG, et al. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail 2012;14(9):1067–1074. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
